Stealth™ Liposomes as Carriers of Doxorubicin
Liposomes, as non-covalently bound carriers, biocompatible and biodegradable, have raised considerable interest as a drug delivery system in cancer chemotherapy (Gregoriadis, 1988). Most applications of liposomes in cancer chemotherapy are directed at altering tissue distribution and various pharmacokinetic parameters of the drug in question in such a way that toxicity can be reduced and/or efficacy increased (Mayhew and Papahadjopoulos, 1983). Reduced toxicity may be gained through site circumvention of drug sensitive tissues and by slow release of the cytotoxic agent from the carrier, avoiding peak plasma concentrations after bolus injection of free drug. Liposome- mediated decrease in toxicity could enable escalation of dose, which will result in increased tumor exposure to the drug.
KeywordsAscitic Fluid Liposomal Doxorubicin Liposomal Drug Free Doxorubicin Anionic Liposome
Unable to display preview. Download preview PDF.
- Gabizon, A., Goren, D., and Barenholz, Y., 1988a, Investigation on the antitumor efficacy of liposome-associated doxorubicin in murine tumor models, Isr. J. Med Sci. 24:517.Google Scholar
- Gabizon, A., Goren, D., Ramu, A., and Barenholz, Y., 1986a, Design, characterization and anti-tumor acticity of adriamycin containing phospholipid vesicles, In: Targeting of Drugs with Synthetic Systems, G. Gregoriadis, J. Senior, G. Poste eds., Plenum, London.Google Scholar
- Goren, D., Horowitz, A.T., Mandelbaum-Shavit, F., Tzemach, D., Zalipsky, S., and Gabizon, A., 1997, In vitro and in vivo studies of folate-targeted liposomes, Proc.Cont. Rel. Soc. 24:865.Google Scholar
- Gregoriadis, G., ed., 1988, Liposomes as Drug Carriers: Recent Trends and Progress, Wiley, London.Google Scholar
- Van Hoesel, Q.G., Steerenberg, P.A., Crommelin, D.J., Van Dijk, A., Van Oort, W., Klein, S., Douze, J.M., de Wildt, DJ., and Hillen, F.C., 1984, Reduced cardiotoxicity and nephrotoxicity with preservation of anti-tumor activity of doxorubicin entrapped in stable liposomes in the Lou/M Ws1 Rat, Cancer Res. 44:3698.PubMedGoogle Scholar
- Lasic, D., and Martin, F., eds., 1995, Stealth Liposomes, Pharmacology and Toxicology series, CRC Press, Boca Raton, FL.Google Scholar
- Mayhew, E., and Papahadjopoulos, D., 1983, Therapeutic application of liposomes. In: Liposomes, M.J. Ostro, ed., Marcel Dekker, New-York.Google Scholar
- Minow, R.A., Benjamin, R.S., and Gottlieb, J.A., 1975, Adriamycin cardiomyopathy; an overview with determination of risk factors, Cancer Chemother. Rep. 6:195.Google Scholar
- Muggia, F.M., Hainsworth, J.D., Jeffers, S., Miller, P., et al., and Liang.-Jung, L.J., 1997, Phase II study of liposomal doxorubicin in refractory ovarian carcinoma: anti-tumor activity and toxicity modification by liposomal encapsulation, J. Clin. Oncol. 15:987.Google Scholar
- Rahman, A., White, G., More, N., and Schein, P.S., 1985, Pharmacological, toxocological and therapeutic evaluation in mice of doxorubicin entrapped in cardiolipin liposomes, Cancer Res. 45:769.Google Scholar